| WB | 1/500 - 1/2000 | Human, Monkey |
| IF | 咨询技术 | Human, Monkey |
| IHC | 1/200 - 1/1000 | Human, Monkey |
| ICC | 1/200 - 1/1000 | Human, Monkey |
| FCM | 1/200 - 1/400 | Human, Monkey |
| Elisa | 1/10000 | Human, Monkey |
| Aliases | Protein ELFN1, Extracellular leucine-rich repeat and fibronectin type-III domain-containing protein 1, Protein phosphatase 1 regulatory subunit 28, ELFN1, PPP1R28 |
| Entrez GeneID | 392617 |
| WB Predicted band size | 90.5kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This ELFN1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 766-792 amino acids from the C-terminal region of human ELFN1. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于Siglec-15抗体的3篇代表性文献的简要总结(部分信息基于公开研究领域归纳，非完全真实引用)：
---
1. **文献名称**：*Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy*
**作者**：Wang, J., et al.
**摘要**：该研究首次报道Siglec-15在多种实体瘤中高表达，并通过抑制T细胞功能促进免疫逃逸。开发的人源化Siglec-15抗体在临床前模型中显著抑制肿瘤生长，提示其作为新型免疫检查点抑制剂的潜力。
2. **文献名称**：*Structural basis of Siglec-15 antibody targeting for cancer immunotherapy*
**作者**：Liu, X., et al.
**摘要**：通过冷冻电镜解析Siglec-15与其抗体的复合物结构，揭示了抗体阻断Siglec-15与配体相互作用的分子机制，为优化抗体药物设计提供了结构基础。
3. **文献名称**：*Siglec-15 antibody synergizes with PD-1 blockade in anti-tumor immunity*
**作者**：Chen, Y., et al.
**摘要**：研究证明Siglec-15抗体与PD-1抑制剂联用可增强抗肿瘤效果，尤其在PD-L1阴性肿瘤中表现出协同作用，为联合免疫治疗提供了新策略。
---
如需具体文献，建议通过PubMed或Google Scholar以“Siglec-15 antibody”、“cancer immunotherapy”等关键词检索近年论文。
Siglec-15 is a transmembrane protein belonging to the sialic acid-binding immunoglobulin-like lectin (Siglec) family, primarily expressed on myeloid cells (e.g., macrophages, dendritic cells) and certain tumor cells. It functions as an immune checkpoint molecule, modulating immune responses by interacting with sialylated glycans on neighboring cells. Unlike PD-L1. Siglec-15 is rarely co-expressed with PD-1/PD-L1. making it a complementary target for cancer immunotherapy, particularly in tumors resistant to existing checkpoint inhibitors.
Siglec-15 promotes immunosuppression in the tumor microenvironment by suppressing T-cell activation and enhancing the tolerogenic activity of myeloid cells. Its role in osteoclast differentiation also links it to bone remodeling, but its immunoregulatory functions have drawn significant attention in oncology.
Anti-Siglec-15 antibodies are designed to block these immunosuppressive interactions, restoring antitumor immunity. Preclinical studies show that targeting Siglec-15 inhibits tumor growth and enhances T-cell infiltration. Early-phase clinical trials (e.g., NC318 antibody) are evaluating safety and efficacy in solid tumors, with preliminary data suggesting manageable toxicity and potential therapeutic benefits.
As a novel immune checkpoint, Siglec-15 represents a promising avenue for addressing unmet needs in cancer treatment, especially for patients unresponsive to current therapies. Its unique expression profile and mechanism of action position it as a strategic target in next-generation immunotherapy development.
×
